Skip to content

Newsroom

Fast Facts

Company Overview

Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully. The Company employs approximately 8,000 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries.

Number of Employees

Allergan employs approximately 8,000 people worldwide and operates world-class research and development facilities and state-of-the-art manufacturing plants. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities, with a presence in more than 100 countries.

Year Founded

1950

Corporate Headquarters

Irvine, California

Chief Executive Officer and Chairman of the Board

David E. I. Pyott

Executive Committee

David E. I. Pyott
F. Michael Ball
Raymond H. Diradoorian
Jeffrey L. Edwards
Douglas S. Ingram, J.D.
Scott M. Whitcup, M.D.

Key Financials

For the quarter ended December 31, 2007

  • Allergan’s total product net sales were $1,075.1 million. Total product net sales increased 31.7 percent, or 27.3 percent at constant currency, compared to total product net sales in the fourth quarter of 2006.
  • Total specialty pharmaceuticals net sales increased 24.5 percent, or 20.3 percent at constant currency, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2006.
  • Total core medical devices net sales increased 70.1 percent, or 65.0 percent at constant currency, compared to total core medical devices net sales in the fourth quarter of 2006.

For the quarter ended September 28, 2007

  • Allergan’s total product net sales were $978.7 million. Total product net sales increased 23.6 percent, or 20.9 percent at constant currency, compared to total product net sales in the third quarter of 2006.
  • Total specialty pharmaceuticals net sales increased 16.1 percent, or 13.4 percent at constant currency, compared to total specialty pharmaceuticals nets sales in the third quarter of 2006.
  • Total core medical devices net sales increased 66 percent, or 62.7 percent at constant currency, compared to total core medical devices net sales in the third quarter of 2006.

For the quarter ended June 29, 2007

  • Allergan's total product net sales were $972.8 million. Total product net sales increased 23.6 percent, or 21.2 percent at constant currency, compared to total product net sales in the second quarter of 2006.
  • Total specialty pharmaceuticals net sales increased 16.2 percent, or 13.9 percent at constant currency, compared to total specialty pharmaceuticals net sales in the second quarter of 2006.
  • Total core medical devices net sales increased 53.6 percent, or 50.8 percent at constant currently, compared to total core medical devices net sales in the second quarter of 2006.

For the quarter ended March 30, 2007

  • Allergan's total product net sales were $872.4 million, which includes $165.2 million of product net sales acquired in connection with the Inamed acquisition. Total product net sales increased 41.8 percent, or 40.0 percent at constant currency, compared to total product net sales in the first quarter of 2006.
  • Pharmaceutical net sales (which exclude product sales acquired in connection with the Inamed, Corneal and EndoArt acquisitions) increased 13.4 percent, or 11.6 percent at constant currency, compared to pharmaceutical net sales in the first quarter of 2006.

2006

  • For the year ending 2006, total product net sales totaled $3.0 billion, a 30 percent increase over 2005. Within the attractive, high-growth markets which it serves, Allergan has steadily increased its market shares.
  • Achieving a major milestone, 2006 sales of BOTOX® crossed the billion-dollar mark on the strength of growth in sales for both therapeutic and cosmetic use, including GlaxoSmithKline's (GSK) sales in Japan and China as a result of Allergan's development and promotion arrangement with GSK. For full year 2006, therapeutic sales accounted for approximately 52 percent of total BOTOX® sales and cosmetic sales accounted for approximately 48 percent of total BOTOX® sales.
  • Sales of LUMIGAN® grew 22 percent over 2005. With sales of $327 million, the LUMIGAN® franchise is currently ranked third largest by value in the world.
  • Sales of RESTASIS® were $270 million, an increase of 42 percent over the prior year.

Allergan Research and Development

  • Allergan increased R&D spending 22 percent in 2006 over 2005, to approximately $500 million.1
  • In 2007, we are again increasing our R&D investment by a similar amount, to approximately $600 million (or approximately 17 percent of product net sales, according to increase 1Q2007 guidance).

Recent Acquisitions

Esprit Pharma Holding Company, Inc.
In October 2007, Allergan acquired Esprit Pharma, Inc. Upon completion of the acquisition Allergan obtained U.S. marketing rights to SANCTURA®, a twice-a-day anthicholinergic approved for the treatment of overactive bladder (OAB), and SANCTURA XR™, a once-daily formulation of SANCTURA®, which has shown to be effective while significantly reducing typical side effects such as dry mouth associated with many OAB medications. Allergan's acquisition of Esprit aligns with Allergan's strategic interest in the urologics market.

EndoArt SA
In February 2007, Allergan announced completion of its acquisition of EndoArt. The acquisition gained Allergan ownership of EndoArt's proprietary technology platform, including FLOWATCH® technology, which powers the EASYBAND® Remote Adjustable Gastric Band System, a next-generation, telemetrically adjustable gastric banding device for the treatment of morbid obesity.

Groupe Corneal Laboratoires
In January 2007, Allergan completed the acquisition of Groupe Corneal Laboratoires, obtaining exclusive rights to market and manufacture the JUVEDÉRM™ dermal filler family of products.

Inamed Corporation
In March 2006, Allergan acquired Inamed Corporation. The acquisition of Inamed expanded Allergan's global position as a premier biomedical company in high-growth markets and created a world-leading medical aesthetics franchise, providing a broad, complementary portfolio of pharmaceutical and medical device products to physicians and patients.


  1. Adjustments to GAAP research and development expense used to calculate research and development expense, adjusted for non-GAAP items, include $579.3 million of in-process research and development expense, $0.2 million of integration and transition costs related to the Inamed acquisition and $0.5 million of transition/duplicate operating expenses related to the restructuring and streamlining of European operations. GAAP research and development expense was $1,055.5 million in 2006, a 171.8% increase over 2005.